- Home
- ALLT vs PVLA Comparison
ALLT vs PVLA Comparison
Compare ALLT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLT
- PVLA
- Stock Information
- Founded
- ALLT 1996
- PVLA 2015
- Country
- ALLT Israel
- PVLA United States
- Employees
- ALLT N/A
- PVLA N/A
- Industry
- ALLT Telecommunications Equipment
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- ALLT Telecommunications
- PVLA Health Care
- Exchange
- ALLT Nasdaq
- PVLA Nasdaq
- Market Cap
- ALLT 313.2M
- PVLA 253.2M
- IPO Year
- ALLT 2006
- PVLA N/A
- Fundamental
- Price
- ALLT $8.73
- PVLA $23.49
- Analyst Decision
- ALLT Buy
- PVLA Strong Buy
- Analyst Count
- ALLT 1
- PVLA 7
- Target Price
- ALLT $13.00
- PVLA $46.29
- AVG Volume (30 Days)
- ALLT 475.0K
- PVLA 59.2K
- Earning Date
- ALLT 05-12-2025
- PVLA 05-15-2025
- Dividend Yield
- ALLT N/A
- PVLA N/A
- EPS Growth
- ALLT N/A
- PVLA N/A
- EPS
- ALLT N/A
- PVLA N/A
- Revenue
- ALLT $93,455,000.00
- PVLA N/A
- Revenue This Year
- ALLT $9.08
- PVLA N/A
- Revenue Next Year
- ALLT $6.09
- PVLA N/A
- P/E Ratio
- ALLT N/A
- PVLA N/A
- Revenue Growth
- ALLT N/A
- PVLA N/A
- 52 Week Low
- ALLT $2.02
- PVLA $11.17
- 52 Week High
- ALLT $9.44
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- ALLT 67.97
- PVLA N/A
- Support Level
- ALLT $8.02
- PVLA N/A
- Resistance Level
- ALLT $8.32
- PVLA N/A
- Average True Range (ATR)
- ALLT 0.40
- PVLA 0.00
- MACD
- ALLT 0.02
- PVLA 0.00
- Stochastic Oscillator
- ALLT 78.28
- PVLA 0.00
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.